De-Risk with AI, Modelling and Experienced Operators
The commercial reality for life sciences innovators is challenging: 62% of pharmaceutical launches underperform Wall Street expectations, 95% of AI-health pilots have challenges to scale, and 80% of digital health initiatives yield zero return on investment.
In this environment, scientific excellence alone is insufficient. Investors, payers, and strategic partners demand demonstrable evidence of de-risked commercial viability, before capital is deployed or teams are scaled.
At Strategic Growth AI, we eliminate commercialization risk through embedded execution, investor-grade analytics, and AI-powered operators who partner directly with your team to deliver measurable, audit-ready outcomes.
Our Three-Phase Execution Framework
Phase 1: Pre-Launch – Validate with Investor-Grade Certainty
Before filing an IND, initiating a funding round, or hiring commercial staff, we pressure-test your go-to-market thesis using PDM™ (Probability-Driven Modeling), a Monte Carlo simulation engine calibrated to North American reimbursement pathways, including CADTH, pCPA, CMS, and FDA 510(k)/De Novo processes.
We deliver a quantified probability of reimbursement approval, revenue scenarios across 1,000+ market-access conditions, and failure-point triggers tied to investor valuation levers such as Time-to-Paid-Claim (TtPC), LTV:CAC, and payer adoption velocity. The outcome is a defensible, data-backed commercial thesis that accelerates fundraising and satisfies even the most rigorous corporate venture arms and institutional investors.
Phase 2: Pilot Phase – Run Structured 3–6 Month Betas with a Kill/Pivot/Scale Protocol
We work with you to co-design and operate real-world pilot programs, not technology demos, with predefined key performance indicators and exit gates powered by SGAI Clarity™, our proprietary intelligence platform.
We monitor clinician adoption velocity, patient engagement depth, real-world evidence quality, and early signals of reimbursement feasibility in real time.
If benchmarks are unmet, we trigger a rapid kill decision, preserving 6 to 12 months of precious runway. If partial signals emerge, we pivot with surgical precision. If validation is achieved, we activate a ready-to-deploy commercial engine for immediate scale.This disciplined approach directly counters the 95% failure rate of AI-health pilots by replacing intuition with objective, data-driven governance.
Phase 3: Post-Launch – Sustain Momentum Through Predictive Intervention
Most launches stall within 12 months due to reactive, not proactive management. We prevent this through continuous AI-driven vigilance. We track Time-to-Paid-Claim (TtPC), the single strongest predictor of commercial sustainability, alongside script conversion lag, HCP engagement decay, and real-world performance against HEOR commitments. When risk signals emerge, we execute pre-approved interventions: rebalancing sales territories, refreshing value dossiers with live real-world evidence, or re-engaging payers with dynamic budget impact models.
Clients consistently achieve 1.5 to 2.3 times faster paid claims and avoid the zero-ROI trap that undermines most digital health commercialization efforts.
Differentiated Execution for Ventures and Investors
Unlike traditional consulting firms that advise from a distance, Strategic Growth AI embeds as your AI-powered operator, executing alongside your team, not just reporting to it. We do not deliver static slide decks; we provide live intelligence, predictive triggers, and milestone-based decision gates.
Our models are not generic financial forecasts; they are North America calibrated simulations tied directly to reimbursement pathways and investor valuation frameworks. And while large consultancies serve multinational pharmaceutical companies, we are purpose-built for emerging ventures, SMEs, and investors who cannot afford failed pilots, delayed reimbursements, or stalled launches.
Proven Impact Across Modalities
In biotech, we accelerated CADTH/pCPA submission success by 70% through early HEOR alignment. In AI-health, we reduced pilot failure risk by 90% via structured 3-month betas with investor-aligned KPIs. In medtech and diagnostics, we achieved 2.1 times faster hospital adoption by integrating FDA strategy with reimbursement evidence generation from day one. And in imaging and devices, we drove 40% higher utilization by embedding real-world workflow validation into pilot design.
North America Entry Focused. AI-Driven. Operator-Led.
Our team combines deep operational fluency in U.S. Inflation Reduction Act (IRA) implications, CMS evidence expectations, and Canada’s evolving CDA/pCPA framework with hands-on experience as former General Managers, reimbursement strategists, and commercial operators, not generalist advisors.
Start building with certainty.
Book Your Commercialization Readiness Audit
De-risked launches. Faster revenue. Higher valuations.